Core Viewpoint - Thermo Fisher is nearing a cash acquisition of Clario, valuing the company at approximately $10 billion, marking a significant move in the clinical trial data management sector [1][2]. Group 1: Acquisition Details - If the acquisition is finalized, it will be Thermo Fisher's largest deal since the $17.4 billion acquisition of CRO PPD in 2021 [2]. - Clario was established in 2021 through the merger of ERT and Bioclinica, focusing on providing clinical trial-related software services to pharmaceutical companies [3]. Group 2: Company Background - Clario's shareholders include notable private equity firms such as Nordic Capital and Astorg, indicating strong backing and expertise in clinical data management and trial operations support [3]. - As of the report, both Thermo Fisher and Clario have not responded to requests for comments regarding the acquisition [4].
赛默飞或将100亿美元收购一公司
仪器信息网·2025-10-29 10:09